J&J dealt blow in fight over its 340B rebate model
A federal judge said the government did not run afoul of the law when it required Johnson & Johnson to seek approval before implementing its proposed 340B rebate model. The Friday decision marks another court …
NVO vs. LLY: Which Obesity Powerhouse is the Stronger Bet Now?
Novo Nordisk NVO and Eli Lilly LLY dominate the diabetes and obesity market on the back of the tremendous success of their GLP-1 products. Novo Nordisk markets its semaglutide drugs as Ozempic pre-filled pens and Rybelsus oral tablets for type II diabetes (T2D) and as Wegovy injection for weight management. Lilly markets its dual GIP and GLP-1 receptor agonist, […]
With China approval, Lilly and Innovent’s mazdutide breaks into new class for GLP-1 obesity drugs
With a first-in-class approval in China, Eli Lilly’s GLP-1 development engine has delivered yet again on the obesity front—although local biopharma outfit Innovent Biologics will be the one to reap the rewards in the near term.
The GLP-1 Weight Loss Drug Ozempic Is Reportedly Giving Men A Lot To Brag About, Down Under
Imagine getting rid of your persistent fat layers, while gaining girth down under. That’s a contemporary equivalent to the fabled fountain of youth, and a special class of weight loss drugs that leverage the GLP-1 hormone – such as Novo Nordisk’s Wegovy or Eli Lilly’s Zepbound – are now being billed as the conduits for […]
Amgen Looks to Take Share of Booming Obesity Space: Will It Succeed?
Amgen AMGN is one of the several drug makers racing to develop the next blockbuster weight loss drug and take a share of the booming weight loss drug market. The obesity market is expected to expand to $100 billion by 2030, according to data from Goldman Sachs. Amgen is developing MariTide, a GIPR/GLP-1 receptor, as a […]
Starbucks Has A GLP-1 Problem
Post Content
Does Medicare Cover Ozempic, Zepbound and Other GLP-1 Inhibitors?
GLP-1 drugs, such as Ozempic, are reshaping diabetes care and weight loss. Find out if Medicare covers them and if they’re right for you.
Innovent brings a new mechanism to obesity market with China approval
Innovent said on Friday that its obesity medicine mazdutide has been approved in China, becoming the first dual GLP-1/glucagon agonist to be greenlit for the disease anywhere in the world. …
GLP-1s linked to cases of illness and death
GLP-1 drugs, which have seen widespread success, have been linked to a number of cases of pancreatitis in the UK, which have led to hospitalisations and even deaths.
STAT+: Pharmalittle: We’re reading about the gray market for obesity meds, an RSV drug recommendation, and more
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is, so far, rather modest. We expect to manicure the Pharmalot grounds, hang with a short person or two, and catch up on […]